ResearchMoz

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

GBI Research
Published Date » 2013-08-30
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs.  
   
 Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Etiology and Pathophysiology
2.2 Classification
2.3 Epidemiology
2.3.1 The US
2.3.2 Obesity in the Top Five European Markets
2.3.3 Japan
2.4 Comorbidities
2.4.1 Type 2 Diabetes
2.4.2 Hypertension
2.4.3 Dyslipidemia
2.4.4 Respiratory Problems
2.4.5 Osteoarthritis
2.4.6 Cancer Risk
2.5 Economic Burden
2.6 Current Therapy Options
2.6.1 Lifestyle and Behavioral Modifications
2.6.2 Bariatric Surgery
2.6.3 Pharmacotherapy
2.6.4 Treatment Algorithms and Prescription Habits
2.6.5 Method of Determining Treatment Effectiveness
2.7 Why Develop Therapeutic Anti-obesity Drugs?
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Amphetamine-like Drugs
3.1.1 Overview
3.1.2 Efficacy Profile
3.1.3 Safety Profile
3.2 Qsymia, Vivus, Inc.
3.2.1 Overview
3.2.2 Efficacy Profile
3.2.3 Safety Profile
3.2.4 Discussion
3.3 Orlistat
3.3.1 Overview
3.3.2 Efficacy Profile
3.3.3 Safety Profile
3.3.4 Discussion
3.4 Belviq, Arena Pharmaceuticals
3.4.1 Introduction
3.4.2 Efficacy Profile
3.4.3 Safety Profile
3.4.4 Discussion
3.5 Low Long-term Success Rate of Marketed Anti-Obesity Drugs
3.6 Discussion

4 Pipeline
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target
4.2 Clinical Trial Duration and Size
4.2.1 Clinical Trial Duration
4.2.2 Clinical Trial Size
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure
4.4 Primary and Secondary Endpoints
4.5 Late-stage Drugs of the Developmental Pipeline
4.5.1 Contrave, Orexigen Therapeutics
4.5.2 Cametor, Norgine BV
4.5.3 Victoza, Novo Nordisk
4.5.4 Tesofensine (NeuroSearch)
4.6 Discussion

5 Market Forecasts
5.1 Global Market
5.2 The US
5.2.1 Epidemiology and Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Europe
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Discussion
5.6 Drivers and Barriers of the Anti-obesity Market
5.7 Obesity Market Drivers
5.7.1 Obesity is a Very Prevalent Disease with Large Potential Target Populations Globally
5.7.2 Recent Approval of Qsymia to Drive Market Growth Providing its Long-term Safety is Proved
5.7.3 Diversification of Molecular Targets
5.8 Obesity Market Barriers
5.8.1 Low Treatment Rate
5.8.2 Reimbursement Issues

6 Licensing and Co-Development Deals
6.1 Licensing Deals
6.1.1 EMD Serono Enters into Collaboration and Licensing Agreement with Theratechnologies
6.1.2 Amylin Pharma Enters into Licensing Agreement with Takeda Pharma
6.1.3 Palatin Technologies Extends License Agreement with AstraZeneca
6.1.4 Zealand Pharma Enters into Licensing and Collaboration Agreement with Boehringer
Ingelheim
6.2 Co-development Deals
6.2.1 Isis Enters into Collaboration Agreement with Ortho-McNeil
6.2.2 Orexigen Therapeutics Enters into Co-development Agreement with Takeda Pharma for
Contrave

7 Appendix
7.1 References
7.2 Abbreviations
7.3 All Pipeline Drugs by Phase
7.3.1 Discovery
7.3.2 Preclinical
7.3.3 Phase I
7.3.4 Phase II
7.3.5 Phase III
7.3.6 Pre-Registration
7.4 Market Forecasts to 2019
7.4.1 Global
7.4.2 The US
7.4.3 UK
7.4.4 France
7.4.5 Germany
7.4.6 Italy
7.4.7 Spain
7.4.8 Japan
7.5 Methodology
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Pipeline Analysis
7.11 Contact Us
7.12 Disclaimer

List of Tables


Table 1: BMI Classifications
Table 2: Key Components of Pathways Thought to be Related to Obesity
Table 3: Treatment Options Dependent on BMI
Table 4: Obesity Therapeutics, Leading Brand Names of Phentermine
Table 5: Efficacy Results* for Qsymia at 52 Weeks
Table 6: Changes in Key Safety Parameters in Patients Treated with Qsymia
Table 7: Sales Data for Xenical ($m), 2008–2011
Table 8: Efficacy Results for Orlistat as an Initial and Maintenance Therapy
Table 9: Safety Results of Orlistat
Table 10: Efficacy Results for Belviq
Table 11: Placebo-adjusted Safety Results for Belviq
Table 12: Obesity Therapeutics Market, Global, Common Molecular Targets in the Obesity Pipeline
Table 13: Obesity Therapeutics Market, Global, Average Clinical Trial Size for the Most Common Modes of
Action Amongst Pipeline Drugs, 2006–2013
Table 14: Obesity Therapeutics Market, Global, Average Clinical Trial Duration for the Main Modes of
Action Amongst Pipeline Drugs, 2013
Table 15: Contrave, Phase III Clinical Trial Results
Table 16: Contrave, Efficacy Results, Phase III Clinical Trial
Table 17: Cametor, Efficacy Results of a Phase II Clinical Trial
Table 18: Cametor, Safety and Efficacy Results, Phase III Clinical Trial
Table 19: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009
Table 20: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009
Table 21: Victoza ,Safety and Efficacy Results, Phase III Clinical Trial, 2009
Table 22: Obesity Therapeutics Market, Europe, Current Prevalence Rate of the Population Which is
Obese or Overweight, 2012–2019
Table 23: Obesity Therapeutics Market: Global, Developmental Pipeline, Discovery Phase
Table 24: Obesity Therapeutics Market: Global, Developmental Pipeline, Preclinical Phase
Table 25: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase I
Table 26: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase II
Table 27: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase III
Table 28: Obesity Pharmacotherapy Market: Global, Developmental Pipeline, Pre-Registration
Table 29: Obesity Therapeutics Market, Global, Market Forecasts, 2012–2019
Table 30: Obesity Therapeutics Market, US, Market Forecasts, 2012–2019
Table 31: Obesity Therapeutics Market, UK, Market Forecasts, 2012–2019
Table 32: Obesity Therapeutics Market, France, Market Forecasts, 2012–2019
Table 33: Obesity Therapeutics Market, Germany, Market Forecasts, 2012–2019
Table 34: Obesity Therapeutics Market, Italy, Market Forecasts, 2012–2019
Table 35: Obesity Therapeutics Market, Spain, Market Forecasts, 2012–2019
Table 36: Obesity Therapeutics Market, Japan, Market Forecasts, 2012–2019

List of Figures


Figure 1: Obesity, Global, Prevalence (%), 1990–2010
Figure 2: Effects of Topiramate on Food Intake
Figure 3: Obesity Therapeutics Market, Obesity Drug Approvals and Market Removals
Figure 4: Obesity Therapeutics Market, Heat Map Comparing the Safety and Efficacy of Marketed Drugs
Figure 5: Obesity Therapeutics Market, Heat Map Comparing the Performance of Marketed Drugs in
Major Safety Parameters
Figure 6: Obesity Therapeutics Market, Global, Pipeline by Phase and Molecule Type and Molecular
Target
Figure 7: Obesity Therapeutics Market, Global, Clinical Trial Duration by Phase and Molecule Type, 2006–
2013
Figure 8: Obesity Therapeutics Market: Global, Clinical Trial Size by Phase and Molecule Type, 2006–2013
Figure 9: Obesity Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Phase and
Molecule Type, 2006–2013
Figure 10: Obesity Therapeutics Market, Global, Clinical Trial Primary and Secondary Endpoints, 2006–2013
Figure 11: Heat Map Comparing the Safety and Efficacy of Marketed and Key Pipeline Drugs
Figure 12: Heat Map Comparing the Performance of Marketed and Key Pipeline Drugs in Major Safety
Parameters
Figure 13: Obesity Therapeutics Market, Global, Epidata and Market Forecasts, 2012–2019
Figure 14: Obesity Therapeutics Market, US, Epidata and Market Forecasts, 2012–2019
Figure 15: Obesity Therapeutics Market, Europe, Treatment Patterns, 2012–2019
Figure 16: Obesity Therapeutics Market, Europe, Annual Cost of Therapy, 2012–2019
Figure 17: Obesity Therapeutics Market, Europe, Market Forecasts, 2012–2019
Figure 18: Obesity Therapeutics Market, Japan, Epidata and Market Forecast, 2012–2019
Figure 19: Obesity Therapeutics Market, Global, Status, Value and Number of Licensing Deals, 2006–2013
Figure 20: Obesity Therapeutics Market, Global, Licensing Deals by Phase, Molecule Type and Value, 2006–
2013
Figure 21: Obesity Therapeutics Market, Global, Status, Value and Number of Co-development Deals,
2006–2011
Figure 22: Obesity Market, Global, GBI Research Market Sizing Model

Upcoming Reports:

Energy Efficient Materials Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Increasing consumption of energy in buildings for various electrical appliances and peripherals has developed the idea of using energy efficient materials in building construction. Energy efficient materials are largely used for thermal insulation of buildings as a result of which, demand for these materials is on the rise. Thermal insulation is the most efficient and effective way to improve the energy utilization and efficiency in the building. This method will preserve the indoor heat during winter while keeping the building cool from inside in summers thus improving...
Dental Diagnostic Equipment Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The market for dental diagnostic equipments consists of devices used in the diagnosis of dental diseases and conditions, so as to enable proper treatment planning. These include intraoral and extraoral radiology equipments and scanners.  Consumption of unhealthy food and improper eating habits has led to an increased incidence of oral diseases worldwide. A growing consumer base opting for dental treatments accompanied by a rise in the number of dental clinics providing such treatment, fuels continuous market growth for this segment. Patients demand painless diagnosis...
Geothermal Exploration Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Geothermal Exploration is the exploration of geothermal resources that can be extracted for the purpose of electricity generation. Geothermal resource is primarily a volume of hot rock and water. Geothermal exploration program implements various techniques to identify geothermal reservoirs and information that can point to high porosity, low density and high permeability areas that can assist in defining well field development. Geothermal exploration takes place in various phases such as Regional reconnaissance, prospect evaluation, project appraisal and exploratory drilling....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Energy Department to Launch New Projects to Protect Wildlife
Apr 16, 2015  
Recently, the Energy Dept. has declared that over US$1.75 million will be spend on five projects which will innovate and demonstrate technologies that decrease the potential negative impacts of wind farms on bat species that are sensitive. Three organizations will be involved in these projects namely the Texas Christian University, Frontier Wind, and the University of Massachusetts....
Biofuel Deal Compromised in Europe
Apr 16, 2015  
Bioenergy is capable of and must contribute to the battle of climate change, however, it is a challenging political route which ensures and reach its sustainability goal. In 2008, the European Parliament had called for inclusions of emission which is associated with indirect land use change or ILUC.  However, the road to reform the policy of EU in this sector has been quite long...
Upcoming Super Highway in China to Influence Energy Trade Flows
Apr 16, 2015  
The strategy of China called Go west has encouraged coastal to inland flow of money and people. It will result in the formation of a new superhighway commodity. This superhighway in China will also impact the energy trade flows in the country and also externally through the new Silk Road routes that are connected to the country’s east to west and onwards to the Central Asia and...
Asian Paints Amalgamates with Citi through the SAP Financial Services Network
Apr 16, 2015  
Asian Paints recently announced the news of integrating its financial transactions with Citi via SAP Financial Service Network.  Financial Service Network of SAP is an integrated platform that provides solution to simplify interaction between financial institutions and corporations. The financial service network will assist Asian Paints to Citi to enjoy the inherent advantages of...
No Other Country in the World Uses Mobile Phone for Banking more than Africa
Apr 16, 2015  
We live in a time wherein a most of us still believes that using for mobile phone for banking transaction of mobile bills is a thing for techies and hipsters. However, a survey released by the World Bank recently reveals surprising findings.  It was revealed by the research that mobile banking technology has penetrated more than we expect it to have. According to a survey released...